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The good news and the bad news
In the past 100 years our grasp of the biology of cancer 
has come a very long way. We now have a working know­
ledge  of  how  tumors  initially  form,  grow  and  spread. 
Importantly, vast amounts of information about features 
distinguishing  tumor  from  normal  cells  is  being 
accumulated, resulting in frequent, major new insights 
into cancer biology.
The bad news is that translating this information into 
the development of new treatments, or even refining the 
use  of  the  ones  we  already  have,  has  been  much  less 
impressive. Clinicians will attest that cytotoxic chemo­
therapy regimens, developed with the limited biological 
information available at the time of their development, 
remain the mainstay of treatment for most cancers. There 
are  a  few  high­profile  examples  of  rationally  and 
molecularly targeted therapies, but we need to do much 
better if we are to shift the entire pattern of treatment to 
drugs that have high potency but mild side effects.
A brief history of old-school and new age drug 
discovery
Several articles have extensively reviewed the history of 
cancer drug development [1] and so here we will only 
pick out the salient points. It is widely accepted, although 
clouded by the secrecy of war [2], that the first tentative 
steps to treating cancer with drugs emanated from the 
observation  that  exposure  to  chemical  warfare  agents 
(‘poison gases’), such as nitrogen mustards, could limit 
the proliferative nature of rapidly dividing lymphoid cells. 
Goodman and Gilman reasoned that this could translate 
into a therapeutic context and used the nitrogen mustard 
mustine to treat a patient with non­Hodgkin’s lymphoma 
[3]. Around the same time, and building on the obser  va­
tion  that  the  vitamin  folic  acid  could  stimulate  acute 
lympho  blastic  leukemia  (ALL)  cells,  Farber  used  folate 
analogs  such  as  aminopterin  and  then  amethopterin 
(metho  trexate) to treat ALL, in what is often heralded as 
the first ‘rational’ drug development approach [4]. Burch­
enal,  Hitchings  and  Elion  used  a  similar  approach  to 
assess  the  potential  of  purine  analogs,  identifying 
6­mercapto  purine (reviewed in [5]). The nitrogen mus­
tards  and  folate  and  purine  analogs  were  much  later 
shown to interfere with DNA replication, in part explain­
ing their anti­tumor activity. In contrast, the alkaloids of 
the Madagascar periwinkle, such as vincris  tine, originally 
identified in the 1950s in a screen for anti­diabetic drugs, 
block  tumor  cell  division,  and  therefore  proliferation, 
largely by inhibiting microtubule polymeri  zation [6]. All 
these therapies remain in clinical use today.
Following the discovery of chemotherapeutics, the next 
significant advance came in the 1960s with the straight­
forward notion of combining drugs. The rationale for this 
came  from  the  treatment  of  tuberculosis,  for  which 
antibiotics, each with a different mechanism of action, 
were  more  effective  when  used  in  combination.  For 
cancer, it was considered that the development of resis­
tance  to  a  battery  of  agents  used  concurrently,  rather 
than a single drug, was less likely. Using this approach, 
Holland, Freireich and Frei pioneered a combination of 
methotrexate and 6­mercaptopurine for treating children 
with ALL (reviewed in [7]). Today, most cancer chemo­
therapy regimens use this same paradigm.
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Anti­hormone therapy has been spectacularly success­
ful in the treatment of breast cancer. Tamoxifen, the most 
successful  of  these  agents,  was  identified  in  the  early 
1960s  as  an  estrogen  receptor  (ER)  antagonist  (more 
correctly, a selective estrogen receptor modulator). This 
drug, originally developed by Walpole’s group at ICI as a 
potential  contraceptive,  showed  its  potential  when 
initially trialed for breast cancer in 1971 [8]. Subsequent 
clinical trials have confirmed the utility of this drug in 
ERα­positive  breast  cancer  patients  and  tamoxifen  has 
now  been  given  to  millions  of  women  and  has  saved 
countless lives.
The impact of biology on cancer drug development at 
this stage was limited; most therapies had been identified 
either by serendipity or had been selected primarily on 
the basis that they could limit cell division. However, in 
the 1970s and 1980s, the advent of gene manipulation 
and  molecular  genetic  analysis  changed  the  nature  of 
biological research forever and with it the drug discovery 
and development process. Molecularly targeted therapies 
could  now  be  contemplated,  that  is,  drugs  that  were 
rationally designed or selected to inhibit the activity of 
specific molecules (Table 1). If used in the right patient 
population ­ on tumors with specific molecular lesions ­ 
these  therapies  promised  significant  tumor  selectivity. 
One of the most remarkable examples of the development 
of such a targeted therapy, to which biological research 
made a critical contribution, is that of imatinib (Gleevec; 
Figures 1 and 2).
Chronic  myelogenous  (or  myeloid)  leukemia  (CML) 
was first identified in 1845 by Bennett and Virchow [9] 
and has been treated with a wide range of drugs [10]. In 
1960,  Nowell  and  Hungerford  described  a  consistent 
chromosomal abnormality ­ the ‘Philadelphia Chromo­
some’,  named  for  the  city  in  which  they  worked  ­  in 
patients with CML [11]. This was later shown by Rowley 
to  be  formed  from  a  reciprocal  translocation  of  DNA 
between the long arms of chromosomes 9 and 22 [12] 
(Figure 1a).
In the 1970s and 1980s several oncogenes present in 
cancer­causing  viruses  were  shown  to  have  normal 
cellular equivalents that became altered in human cancers. 
For  example,  the  Abelson  murine  leukemia  retro  virus 
(A­MuLV) [13] was shown to carry a transforming gene 
(vABL) that had a normal cellular homolog, cABL [14]. 
Subsequently, the cABL gene was shown to be involved in 
the chromosomal rearrangement in CML, translocating 
from  chromosome  9  to  the  breakpoint  cluster  region 
(BCR) gene on chromosome 22 [15,16] (Figure 1a). This 
results in the production of a fusion gene between BCR 
and cABL [17]. In 1981, vABL had been identified as a 
protein kinase [18] and the BCR-ABL fusion mRNA was 
later  shown  to  encode  a  constitutively  active  kinase 
whose  activity  could  transform  cells  both  in  vitro  [19] 
and  in  vivo  [20,21].  Therefore,  it  was  recognized  that 
targeting the catalytic activity of ABL could potentially 
deliver a therapeutic window between tumor cells with 
constitutive activity of BCR­ABL and normal cells with 
more tightly controlled ABL activity. Subsequent studies 
on BCR­ABL biology have focused on defining the links 
between  BCR­ABL  activity  and  the  pathological 
characteristics of CML and other diseases [22].
At the same time as the transforming activity of BCR-
ABL  had  been  established,  several  observations  were 
made that, while not critical to understanding the biology 
of  BCR­ABL  and  CML,  were  absolutely  crucial  to  the 
eventual development of drugs used to treat the disease. 
First,  it  was  recognized  that  certain  small  molecules 
could inhibit the activity of protein kinases [23]. Second, 
methods for expressing large amounts of active human 
proteins in insect cells were refined, allowing BCR­ABL 
protein  to  be  generated  to  enable  a  drug  development 
program  [24].  Finally,  antibody  production  technology 
had progressed to such a point that the activity of protein 
kinases could be monitored in a relatively robust manner. 
All of these factors enabled a team led by Matter at Ciba­
Geigy  to  initiate  a  kinase  small  molecule  inhibitor 
development program. By 1996, STI517 (imatinib) had 
been identified and its activity confirmed in BCR­ABL 
cells  by  Druker  and  colleagues  [25].  In  1998,  phase  I 
clinical trials commenced [26], leading to drug approval 
by the US Food and Drug Administration in 2001.
At  this  time,  the  first  resistance  mechanisms  to 
imatinib were identified [27]. These could have been due 
to  mechanisms  previously  noted  for  chemotherapy 
resistance, such as enhanced metabolism or efflux of the 
drug  from  cells.  However,  in  what  turned  out  to  be  a 
general phenomenon, Sawyers and colleagues [27] identi­
fied BCR­ABL mutations in patients who had relapsed on 
imatinib treatment, which rendered the enzyme resistant 
to  the  inhibitory  effects  of  imatinib  [28].  The  use  of  a 
three­dimensional  structure  of  the  catalytic  domain  of 
ABL in a complex with an imatinib variant [29] also gave 
insight  into  this  phenomenon  and  has  furthered  our 
understanding of the mode of action of imatinib and the 
second­generation ABL inhibitors such as nilotinib [30] 
and  dasatinib  [31].  These  latter  drugs  can  overcome 
resistance caused by some, but importantly not all, BCR­
ABL  mutations.  Very  recently,  allosteric  inhibitors  of 
ABL have been identified [32] (allosteric being shorthand 
for  ‘binding  outside  the  catalytic  site’).  These  latter 
molecules  bind  the  myristate  binding  site  of  ABL,  as 
opposed to the ATP binding site targeted by imatinib and 
related inhibitors. This inhibitor­target interaction does 
however,  induce  a  structural  change  in  the  catalytic 
domain of the kinase and this in turn inhibits the enzyme 
activity of ABL. When combined with imatinib, an ABL 
allosteric  inhibitor  can  overcome  resistance  caused  by 
Lord and Ashworth BMC Biology 2010, 8:38 
http://www.biomedcentral.com/1741-7007/8/38
Page 3 of 12
BCR­ABL mutations such as T315I [32], illustrating the 
potential  benefit  of  combining  different  modes  of 
inhibition on the same target.
As a final note in the imatinib story, biological insight 
has been used to expand the range of patients that might 
be treated by this drug. As well as ABL, imatinib also 
inhibits  related  kinases,  such  as  the  cytokine  receptor 
cKIT  and  platelet­derived  growth  factor  receptors 
(PDGFRs).  Constitutively  active  cKIT  mutations  are 
found in gastrointestinal stromal tumors and transloca­
tions in the PDGFRB gene are found in diseases such as 
chronic  myelomonocytic  leukemia  (CMML).  Imatinib 
has already shown considerable success for the treatment 
of gastrointestinal stromal tumors [33] and preliminary 
results  suggest  that  it  could  also  work  in  CMML 
characterized by PDGFRB alterations [34].
Table 1. Some examples of targeted therapies for cancer
Drug Brand name Drug target* Cancer types 
In clinical use
   Bevacizumab Avastin VEGF Colorectal, non-small cell lung, breast, renal
   Bortezomib Velcade Proteasome Myeloma, lymphoma
   Celecoxib Onsenal COX2 Familial adenomatous polyposis
   Erlotinib Tarceva
EGFR Non-small cell, lung, colorectal, head and neck
   Gefitinib Iressa
   Cetuximab Erbitux
   Panitumumab Vectibix
   Imatinib Gleevec
BCR-ABL, cKIT, PDGFR Leukemia, gastrointestinal    Dasatinib Sprycel
   Nilotinib Tasigna
   Methotrexate DHFR Multiple cancer types
   RAD001 Certican
mTOR Renal
   Temirolimus Toricel
   Sorafenib Nexavar
VEGFR, RAF, cKIT, PDGFR Renal, hepatic
   Sunitinib Sutent
   Topotecan Hycamtin
Topoisomerase I Multiple cancer types
   Irinotecan Camptosar
   Trastuzumab Herceptin ERBB2 Breast 
   Lapatinib Tykerb HER2, EGFR Breast
   Tamoxifen Nolvadex ERα Breast
   Exemestane Aromasin
Aromatase cytochrome P450 Breast    Anastrozole Arimidex
   Letrozole Femara
   Rituximab MabThera
CD20 Lymphoma
   Tositumomab Bexxar
In development
   17AAG HSP90
   ABT-737, ABT-263, Obatoclax BCL-XL, BCL-2
   Alvocidib CDKs
   Olaparib, AG014699 PARP1/2
   BEZ235 PI3K
   GRN163L hTERT
   Mapatumumab TRAIL Receptor
   Nutlin-3 MDM2
   PLX4032 BRAF
   GDC-0449 SMO
   PF-0477736 CHK1
*Target abbreviations: BCL-2, anti-apoptotic protein BCL-2; BCL-XL, anti-apoptotic protein BCL extra large; BCR-ABL, fusion protein of breakpoint cluster region and 
tyrosine kinase ABL1; BRAF, protein tyrosine kinase BRAF; CD20, B-cell phosphoprotein CD20; CDKs, cyclin-dependent kinases; CHK1, serine/threonine kinase CHK1; 
cKIT, tyrosine kinase c-KIT; COX2, cyclooxygenase 2; DHFR, dihydrofolate reductase; EGFR, epidermal growth factor receptor; ERα, estrogen receptor α; HER2, human 
epidermal growth factor receptor 2; HSP90, heat shock protein 90; hTERT, telomerase reverse transcriptase; MDM2, murine double minute 2; mTOR, mammalian target 
of rapamycin; PARP1/2, poly(ADP-ribose) polymerase 1/2; PDGFR, platelet-derived growth factor receptor; PI3K, phosphatidylinositol 3-kinase; RAF, small GTPase RAF; 
SMO, Smoothened; TRAIL receptor, TNF-related apoptosis-inducing ligand receptor; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor.
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Similar  successful  approaches  have  resulted  in  the 
targeting of other oncogenes, such as epidermal growth 
factor receptor (EGFR; targeted by gefitinib and erlotinib, 
whose brand names are Iressa and Tarceva, respectively 
[35])  and  Human  epidermal  growth  factor  receptor  2 
(HER2; targeted by trastuzumab/Herceptin [36]). More 
recently, the targeting of oncogenic Hedgehog signaling 
in medulloblastoma and basal cell carcinoma [37,38] has 
also  shown  considerable  promise  (Figure  3).  Hedgehog 
(hh) was originally discovered by Nüsslein­Volhard and 
Wieschaus  nearly  30  years  ago  as  a  ‘segment  polarity’ 
gene that controls Drosophila embryonic cuticle pattern­
ing [39]. Vertebrate orthologs of hh were identified in the 
early  1990s  and  subsequent  studies  have  not  only 
dissected the mechanisms underlying hedgehog signaling 
but have also shown Hedgehog to be involved in various 
aspects of animal development, from cell fate through to 
body  length  [40].  Importantly,  Hedgehog  signaling  has 
been  shown  to  be  dysregulated  in  human  cancers, 
notably gastrointestinal tumors, prostate cancer, hemato­
logical malignancies and gliomas. Recent clinical studies 
suggest that medulloblastomas and basal cell carcinomas 
that rely on Hedgehog signaling can be treated with a 
small  molecule  inhibitor  that  targets  the  hh  signaling 
mediator, Smoothened [37,38].
Another notable advance in targeted therapy develop­
ment  has  been  in  the  development  of  small­molecule 
inhibitors  of  the  oncogenic  protein  BRAF  [41,42].  The 
BRAF  gene,  a  viral  oncogene  homolog  that  encodes  a 
Figure 1. Targeted therapy for chronic myelogenous leukemia 
(CML). (a) One of the more common molecular changes in 
hematopoietic cells from CML patients is a reciprocal translocation 
(swap) of DNA between the long arms of chromosomes 9 and 22. 
This translocation forms the ‘fusion’ gene BCR-ABL, which encodes a 
constitutively active ABL kinase. (b) The constitutive activity of BCR-
ABL in hematopoietic CML cells drives several candidate oncogenic 
signaling pathways. Hematopoietic cells in CML patients are 
‘addicted’ to BCR-ABL signaling such that BCR-ABL inhibition impairs 
their viability. (c) Tyrosine kinases such as ABL and BCR-ABL have 
well defined catalytic domains that bind ATP and use its phosphate 
moiety to post-translationally modify substrate proteins. Drugs such 
as imatinib bind and block the catalytic domain and in doing so limit 
hematopoietic cell proliferation in CML patients. (b) and (c) modified 
from [75] and [76].
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Figure 2. Biology-driven cancer drug development for CML. 
From the original description of CML in 1845, fundamental biology 
has driven the development of treatments for CML. Approximate 
times are shown for key events in the development of imatinib.
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kinase  involved  in  the  RAS/RAF/MEK/ERK  pathway 
(Figure 1b), is mutated in up to 70% of melanomas, with 
mutations  such  as  BRAF  V600E  causing  constitutive 
MEK/ERK  activation.  This  MEK/ERK  activation  drives 
tumour cell proliferation and survival. Although there are 
various approaches designed to target RAS/RAF/MEK/
ERK  signaling  [41],  much  effort  has  been  placed  in 
designing small­molecule BRAF inhibitors [42]. Clinical 
studies  now  suggest  that  targeting  constitutively  active 
BRAF in patients with melanomas or colorectal tumors 
characterized by V600E mutations can have significant 
clinical benefit [43] and, very recently, a detailed study of 
BRAF/RAS/CRAF  signaling  interactions  has  provided 
further  insight  into,  and  potential  refinement  of,  this 
approach [44].
Of course, although targeted therapies are heralded as a 
considerable  advance  from  standard  chemotherapies, 
they are still affected by resistance and toxicity effects. 
Returning  to  imatinib,  BCR-ABL  mutations  can  drive 
resistance [27,28], and moderate side effects of imatinib 
treatment, such as edema, do occur. However, with other 
targeted  agents,  such  as  sunitinib,  toxicities  such  as  a 
hand and foot skin reaction can be more severe and in 
fact dose­limiting. Some of these toxicities are likely to be 
caused by inhibition of the desired therapeutic target in 
normal tissues, whereas others may be due to the multi­
kinase  inhibition  profile  of  some  of  the  drugs  used 
clinically. Nevertheless, targeted agents are generally well 
tolerated  compared  with  chemotherapies  and  tend  to 
deliver larger therapeutic windows.
In  summary,  in  contrast  to  more  traditional  cancer 
therapies, the development, clinical use and refinement 
of imatinib and other targeted therapies could not have 
occurred  without  the  considerable  groundwork  of 
biologists from many different disciplines. Nevertheless, 
putting this together required the vision and application 
of individuals willing to apply these developments.
The future of cancer research?
We do need to recognize and applaud the progress that 
has  been  made  in  biologically  targeted  therapeutic 
develop  ment.  This  is  a  great  validation  of  the  role  of 
biological insight, but how this field might develop in the 
future is less clear. To frame this discussion, it is worth 
noting  some  of  the  key  problems  currently  faced  in 
cancer therapy.
First, there are some effective drugs but they are not 
used in an optimal manner. For some cancer types, there 
are  a  series  of  drugs  that  work  relatively  well  but  the 
response  to  them  is  very  heterogeneous.  We  need  to 
understand the reasons for this heterogeneity and tailor 
the right treatment to the individual patient, rather than 
finding  the  best  for  the  average  patient.  Second,  more 
often  than  not,  even  after  an  initial  response,  patients 
frequently relapse ­ we need a clearer understanding of 
the mechanisms underlying relapse and drug resistance if 
we are to overcome them. Third, for some cancer types, 
Figure 3. Targeting oncogenic Hedgehog signaling. (a) In normal cells the Patched homolog, PTCH1, blocks the activation of the Smoothened 
homolog, SMO. Binding of Hedgehog ligand to PTCH1 removes the repression of SMO, and this drives transcriptional changes via the activity of GLI 
proteins. (b) In tumors such as basal-cell carcinoma and medulloblastoma, mutations in PTCH1 or SMO lead to constitutive, ligand-independent 
signaling and an addiction to hedgehog signaling. (c) Blocking the activity of SMO with a small molecule, GDC-0449 can ablate hedgehog signaling 
and thus inhibit cell growth in addicted tumor cells.
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there are no really effective therapies and we need to iden­
tify new drug targets and develop methods of exploit  ing 
them.  And  finally,  with  the  exception  of  a  minority  of 
cancers, preventative strategies are not available.
A fair assessment of the situation would be that we are 
a  considerable  way  off  from  solving  these  problems. 
Understanding more about the biology of cancer will be 
key if we are to make significant advances. But we do 
need to go a step further; biologists need to be continually 
alert to the possibility of translating their findings into 
changing clinical practice. Several recent conceptual and 
experimental  advances  might  help  achieve  this  but,  in 
short,  all  cancer  biologists  need  to  become,  in  part, 
‘translational’.
A deeper understanding of the altered universe of 
the cancer cell
Understanding normal cell behavior has been a signifi­
cant  goal  of  modern  biology  and  of  course  this  is 
extremely important in defining the neoplastic process. 
However,  it  is  now  widely  recognized  that  this  is  not 
enough in itself as there are a constellation of changes in 
the altered and forever adapting universe of the cancer 
cell. Hanahan and Weinberg [45] summarized an immense 
body of work by listing the ‘hallmarks’ of cancer cells and 
tumors  ­  a  limitless  replicative  potential,  resistance  to 
apop  tosis,  insensitivity  to  anti­growth  signals,  self­
sufficiency in growth signals, tissue invasion and meta­
stasis, and sustained angiogenesis. Building on this model 
and  our  deeper  understanding  of  cancer  biology,  Luo, 
Solimini  and  Elledge  [46]  have  proposed  additional 
charac  teristics,  such  as:  evading  immune  surveillance 
[47];  an  elevated  DNA  damage/replication  response 
caused by elevated replication rates and also DNA repair 
defects  in  tumor  cells  [48];  proteotoxic  stress  ­  an 
increase  in  the  amount  of  toxic,  unfolded  proteins  in 
tumor cells and the resultant heat shock protein response 
[49]; mitotic stress/chromosomal instability [50]; meta­
bolic stress ­ the increased use of glycolysis rather than 
oxidative phosphorylation as a means of producing ATP 
[51];  and  oxidative  stress  ­  an  increase  in  the  level  of 
reactive oxygen species in tumor cells [52].
The  obvious  translational  output  of  defining  these 
characteristics  is  in  identifying  additional  means  by 
which  tumor  cells  can  be  targeted.  For  example,  the 
renewed  interest  in  cancer  cell  metabolomics  and 
metabolic  stress  [53]  will  most  likely  lead  to  therapies 
that target tumor­specific reliances on particular aspects 
of glucose metabolism. Furthermore, the classification of 
these characteristics presents significant new opportu  ni­
ties for reinvention of the combination therapy paradigm 
for cancer therapy. Combinatorial targeting of different 
‘hallmarks’ of cancer with targeted therapies (Figure 4) 
could elicit an enhanced and durable therapeutic res  ponse, 
as is seen with combinations of classical chemotherapies.
Embracing the complexity of the cancer cell
The control of cell growth and behavior has long been 
recognized to be complex. However, we are increasingly 
daunted  by  exactly  how  great  a  challenge  it  will  be  to 
understand or predict normal cell behavior or the rewir­
ing that goes on in cancer cells. There are some recent 
examples  in  which  the  discovery  of  entire  levels  of 
cellular regulation, such as microRNAs, add yet another 
layer of complexity.
Moreover, our restricted and naive view of biology has 
meant that, in general, understanding cell behavior has 
been by studying discrete pathways. These pathways are 
often  a  misleading  oversimplification  of  the  complex 
molecular networks that control cell behaviour. However, 
help  may  be  at  hand  in  addressing  this  complexity  in 
‘systems’ approaches. Although still in their infancy, these 
computational  approaches  coupled  with  deep  trans­
criptomic,  genomic  proteomic  or  metabolic  profiling 
promise an integrated approach and, with this, a better 
understanding  of  interacting  molecular  networks.  This 
should  allow  us  to  start  thinking  seriously  about  how 
drugs  perturb  networks  rather  than  discrete  pathways 
and use this information to develop new ‘network’ thera­
peutic strategies.
A  significant  challenge  in  cancer  drug  development, 
‘drugging  the  undruggable’,  is  being  addressed  by 
exploiting molecular networks. An example has been the 
use of poly(ADP­ribose) polymerase (PARP) inhibitors to 
treat  BRCA­deficient  cancers.  BRCA1  and  BRCA2  are 
both classical tumor suppressor genes: loss­of­function 
mutations  disable  BRCA1  and  BRCA2  proteins  and 
strongly predispose to cancer. Targeting tumor suppres­
sor genes presents a particular problem: unlike gain­of­
function oncogenic events such as the BCR-ABL fusion, 
it is not obvious how to pharmacologically target a tumor 
suppressor  protein  that  is  dysfunctional  or  even  com­
pletely absent. However, exploiting knowledge of mole­
cular  networks  may  be  of  significant  benefit  here.  In 
2005, we demonstrated that tumor cells with deficiencies 
in either the BRCA1 or BRCA2 tumor suppressor genes 
are over 1,000 times more sensitive to potent inhibitors 
of the DNA repair protein PARP [54]. Underlying these 
observations  is  a  network  of  synthetically  lethal  genes 
(Figure 5a).
Two  genes  or  proteins  are  synthetically  lethal  when 
inactivation of either gene/protein is still compatible with 
cellular  viability  but  inactivation  of  both  leads  to  cell 
death [55]. Often, synthetic lethal relationships represent 
networks  of  proteins  that  show  a  form  of  functional 
buffering,  and  this  seems  to  be  the  case  with  BRCA 
proteins  and  PARP.  PARP  is  involved  in  the  repair  of 
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DNA breaks in a single strand of DNA. In normal cells, 
PARP inhibition and the resultant increase in DNA single 
strand breaks is functionally compensated for by a second 
form of DNA repair, homologous recombination. Homo­
lo  gous  recombination  is  controlled  by  BRCA1  and 
BRCA2  ­  when  BRCA  proteins  are  defective,  as  is  the 
case in tumors from breast, ovarian and prostate cancer 
patients  carrying  germline  BRCA  gene  mutations,  this 
functional buffering is lost, and cells become exquisitely 
sensitive to PARP inhibitors (Figure 5b,c). These original 
in vitro observations have been translated into clinical 
trials  and  early  results  suggest  significant  tumor 
responses  accompanied  by  relatively  mild  side  effects 
when compared with standard chemotherapies [56]. This 
suggests that the large therapeutic window observed in 
the  laboratory  may  indeed  translate  into  the  clinic. 
Although  expanded  clinical  trials  are  needed  to  prove 
that  such  synthetic  lethal  approaches  really  do  deliver 
larger therapeutic windows, the preliminary indications 
are that exploiting molecular networks may be a viable 
approach.
As discussed above, a large amount of effort has also 
been  invested  in  targeting  oncogenes  as  therapeutic 
targets. It is thought that tumor cells can be ‘addicted’ to 
Figure 4. Hallmarks of cancer. The dissection of cancer biology has allowed the characteristics of tumor cells to be more accurately detailed. Drug 
classes targeting each of the characteristics are also shown (outside ring). Adapted from [46].
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Figure 5. A synthetic lethal network exploited in cancer treatment. (a) Two genes or proteins are synthetically lethal when inactivation of 
either gene/protein is still compatible with cellular viability but inactivation of both leads to cell death [55]. Often synthetic lethal relationships 
represent networks of proteins that show a form of functional buffering. (b) A model for synthetic lethality using PARP inhibitors [54]. DNA is 
constantly damaged, both by environmental and by normal physiological processes. One of the more common forms of DNA damage is the 
formation of DNA single strand breaks (SSBs; step 1). SSBs are normally rapidly repaired by a process known as base excision repair (BER). BER is 
instigated by the activity of the poly(ADP ribose) polymerase, PARP1, and when PARP1 is inhibited (an example PARP inhibitor is shown), SSBs persist 
(step 2). As cells enter S phase, and DNA is replicated; replication forks are eventually stalled by persistent SSBs (step 3; the direction of a replication 
fork is shown by the green arrow). If not rapidly repaired, stalled replication forks can often degenerate and form DNA double strand breaks 
(DSBs), which are highly likely to be lethal (step 4). In normal cells, an additional DNA repair process, homologous recombination (HR), can repair 
stalled replication forks and DSBs (step 5). HR is mediated by BRCA1 and BRCA2 and acts as a functional buffer to enable normal cells to survive 
the effects of PARP and BER inhibition. Conversely, in patients with germ-line BRCA gene mutations, tumor cells show a severe HR defect (step 6). 
PARP inhibition combined with HR deficiency leads to tumor cell death either driven by the formation of lethal DSBs or because mutagenic forms 
of repair predominate in the absence of HR. The genomic instability that follows the use of these non-HR forms of DSB repair eventually limits the 
fitness and viability of tumor cells. (c) Synthetic lethality in in vitro cell culture. Clonogenic assays, which estimate tumor cell survival, demonstrate 
that tumor cells with either BRCA1 or BRCA2 deficiency are profoundly sensitive to potent PARP inhibitors such as KU0058948 (Kudos/AstraZeneca). 
Reproduced, with permission, from [54]. In vitro synthetic lethality translates into clinical synthetic lethality [56]. Computed tomographic (CT) scans 
of the abdomen in a patient with advanced ovarian cancer and BRCA mutation family history showed a reduction in the size of a peritoneal tumor 
nodule by 66% over a 4-month treatment period during which she received a potent PARP1 inhibitor, olaparib, at a dose of 100 mg, twice daily, for 2 of 
every 3 weeks. CT scans of the abdomen in another patient with advanced ovarian cancer, who had a BRCA1 mutation (4693delAA), showed complete 
regression of a peritoneal tumor nodule over a 4-month treatment period with olaparib (200 mg, twice daily) for a year.
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the  activity  of  an  oncogene  [57],  such  that  once  the 
oncogene activity (or the pathway it controls) is blocked, 
tumor cells can no longer survive. Therefore, if one can 
identify an activated oncogene that a tumor cell is addicted 
to,  there  is  the  possibility  of  therapeutic  approach  to 
inhibit  it.  However,  a  significant  problem  arises  if  the 
target  is  not  particularly  suited  to  pharmacological 
inhibition. For example, a significant number of tumors 
are  driven  by  either  MYC  or  RAS  oncogenes,  but  as 
transcription  factors  and  GTPases,  respectively,  these 
proteins have been difficult to target, compared with, for 
example, protein kinases such as BCR­ABL.
One  solution  is  to  exploit  molecular  networks;  the 
activity  of  oncogenes  such  as  MYC  or  RAS  results  in 
considerable adaptive rewiring of cellular networks and 
tumor  cells  may  become  ‘addicted’  to  these  changes. 
These ‘non­oncogene addictions’ [46] could be therapeu­
tically targeted. By performing high­throughput loss­of­
function genetic screens that exploit RNA interference 
technology  [58],  Gilliland  and  colleagues  [59]  showed 
that tumor cells with mutant RAS have acquired a depen­
dence  on  the  kinase  STK33;  tumor  cell  molecular 
networks  have  been  re­wired  such  that  STK33  now 
becomes critical whereas it is not in normal cells. Studies 
by Elledge and colleagues [60] and Hahn and colleagues 
[61]  have  also  identified  additional  addictive  effects  in 
tumor cells that depend on RAS activity and similar work 
has elicited targets for MYC­driven cancers [62]. Whether 
these effects can ultimately be exploited therapeutically 
remains to be seen, but these proof­of­principle experi­
ments clearly highlight the potential for network targeting.
Akin to the approach of exploiting the complexity of 
cancer cells, the integration of multiple data types is also 
now  proving  a  powerful  tool  to  identify  novel  cancer 
drug  targets.  This  is  proving  particularly  true  when 
functional  genomic  screens,  such  as  those  using  RNA 
interference, are combined with molecular profiling tech­
niques.  For  example,  Hahn  and  colleagues  recently 
screened a small panel of colorectal tumor cell lines with 
an RNA interference library to identify CDK8, a gene that 
not  only  controlled  tumor  cell  viability  but  also 
modulated  WNT  signaling,  an  oncogenic  pathway 
commonly active in colorectal cancer [63]. By integrating 
these screen data with the genetic profiles of colorectal 
adenocarcinomas,  they  demonstrated  that  the  CDK8 
gene  was  also  amplified  in  a  significant  proportion  of 
colorectal tumors, suggesting that it could be a promising 
drug target. Furthermore, the CDK8 gene copy alteration 
could  also  serve  as  a  biomarker  with  which  to  select 
patients for treatment with a CDK8 targeting agent, once 
developed. Similar studies have also used the integration 
of a wide variety of disparate data types, such as gene 
expression profiles, immunohistochemical profiles, meta­
bolic profiles and forms of functional analysis, to identify 
novel cancer drug targets [64,65]. With the availability of 
technology,  such  as  next  generation  sequencing,  that 
offers the rapid dissection of cancer genome and trans­
criptome sequences [66­70], these integrated approaches 
are likely to become commonplace.
These next generation profiling technologies may also 
allow us to further our understanding of intra­ and inter­
tumor  heterogeneity.  It  is  well  established  that  tumors 
from  patients  with  diseases  that  are  similar  in  clinical 
presentation are often distinct at the molecular level (for 
example,  in  terms  of  the  transcriptomic  profile  or 
genomic content). Furthermore, heterogeneity also exists 
between primary and metastatic lesions from the same 
patient and also within individual tumors. It is likely that 
this  heterogeneity  explains,  in  part  at  least,  differing 
responses to therapy between ostensibly similar tumors. 
One approach to understanding this heterogeneity is to 
first catalog it, and much effort has already gone into the 
characterization of tumor heterogeneity at the genomic 
and transcriptomic levels, with a seminal example being 
the gene expression profiling of 65 breast tumors [71].
With the advent of next generation sequencing we are 
now seeing the first reports of base­pair resolution DNA 
sequences of human tumors [68,69]. This trickle will turn 
into a torrent as the cost of these profiling approaches 
falls, allowing us to properly address heterogeneity and to 
further tailor treatment to the individual. Nevertheless, 
the first few tumor genome DNA sequences are already 
informing our understanding of cancer biology and hint­
ing at therapeutic approaches. For example, the partial 
DNA sequence of a range of breast tumors and tumor cell 
lines already suggests that particular DNA repair defects 
are  present,  as  represented  by  the  specific  patterns  of 
DNA deletion and rearrangement that are left behind as 
footprints in the tumor genome [69]. Similarly, the type 
and number of mutations found in the genome sequences 
of a melanoma cell line and a lung tumor cell line [68,69] 
seem  to  reflect  the  environmental  agents  (exposure  to 
ultraviolet  light  and  tobacco  use,  respectively)  that 
initially fostered tumorigenesis. Such base­pair resolution 
DNA sequences could be used as diagnostics to identify, 
for example, specific DNA repair defects and to select 
therapies accordingly. Similar advances in proteomic [72] 
and  also  metabolic  [73]  profiling  could  also  address 
heterogeneity and inform therapeutic development. It is 
of course implicit that with this wealth of biological data, 
we need to make advances in our ability to process and 
analyze such large data collections.
Biology-driven cancer drug development
Returning to the here­and­now, there are several organi­
za  tional  and  logistical  roadblocks  to  the  application  of 
basic  research  in  cancer  therapeutic  development  that 
have made this avenue daunting to many biologists. The 
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first is understanding and recognizing the actual clinical 
issues. This means that interactions with clinicians who 
understand  the  benefits  of  basic  research  need  to  be 
fostered and a meaningful dialog established that over­
comes the sometimes arcane jargon used in each field. 
Access to tumor tissue has also been a problem and the 
role  of  the  pathologist  is  critical  here.  Pathologists, 
especially the new generation of molecular pathologists, 
can  also  provide  the  pivotal  link  between  basic  and 
clinical  research.  Finally,  applied  translational  research 
has  frequently  been  seen  as  inferior  to  ‘pure’  basic 
research. With the application of cutting edge technology 
and  fundamental  biological  principles  to  translational 
research, it’s clear that addressing clinical realities is as 
pure a science as any.
Increasingly, biology needs to have a strong role in the 
design  and  analysis  of  clinical  trials.  It  is  generally 
accepted that targeted cancer drugs cannot be used on a 
‘one  size  fits  all’  model  and  trials  need  to  reflect  the 
original fundamental biology. This means designing trials 
with  solid  pre­clinical  laboratory  work  and  where  the 
patient  subgroup  to  be  treated  is  refined  according  to 
precise biomarkers, such as specific oncogene mutations. 
We  argue  elsewhere  (AA  and  JS  DeBono,  unpublished 
work)  that  biomarkers  for  drug  efficacy  and  patient 
selection need to be developed and integrated very early 
in the clinical trials process, such as in phase 1. Again, 
this  means  that  biologists  need  to  work  closely  with 
clinicians as drugs are developed, which in the past has 
been highly unusual. Likewise, studying cancers in the 
neo­adjuvant  context  (before  definitive  surgery)  or  in 
short ‘window of opportunity’ studies (where a therapy is 
administered  and  its  molecular  consequences  closely 
followed using biopsies over a relatively short period of 
time or ‘window’) provides a wealth of material for the 
biologist to study drug responses in real tumors in situ. 
Finally, at least in the advanced cancer setting, resistance 
is at present almost inevitable, and the ability to obtain 
and study metastatic biopsies will be critical in under­
standing  these  mechanisms.  Moreover,  this  will  allow 
testing  of  hypotheses  developed  in  cell  line  or  animal 
models of drug resistance in the genuine clinical context 
[74].
Most cancer drug development is now biology driven. 
However, to ensure that fundamental new insights into 
the  biology  of  cancer  are  used,  it  is  essential  that 
integrated approaches are used. This operates both at the 
level of the experimental approaches, taking full account 
of  the  complexity  of  cancer,  but  also  at  the  level  of 
interaction  of  different  disciplines.  Although  the  trend 
will be towards ‘big’ science, there is still an important 
role for the biologist in proving insight from hypothesis­
based approaches as long as this is applied appropriately. 
A  large  number  of  significant  challenges  in  cancer 
remain,  such  as  the  relentless  plasticity  of  the  cancer 
genome and the Darwinian selection of resistance that 
results. However, with a true concord between biologists, 
oncologists, pharmaceutical companies and patients we 
believe that what we all want can be achieved: effective 
treatments for cancer.
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